Takeda has returned to back the cancer therapeutics developer’s series D round after committing $120m in equity and milestone financing just over 18 months ago.

US-based immunotherapy developer Turnstone Biologics has raised $80m in series D funding from investors including Takeda Ventures, the corporate venturing arm of pharmaceutical firm Takeda.

Investment manager PFM Health Sciences and venture capital firm Point72 co-led the round, which included investment and financial services group Fidelity’s F-Prime Capital unit and fellow existing backers Versant Ventures, OrbiMed, Sectoral Asset Management, Sixty Degree Capital, Brace Pharma Capital and Teralys Capital.

The round also featured new investors Eventide Asset Management, Citadel’s Surveyor Capital…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Edison Fu

Edison Fu is a reporter and Asia liaison at Global Corporate Venturing.
Email LinkedIn